You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab

 

Online download statistics by month:

Online download statistics by month: November 2023 to August 2024

AbstractFullPdf
Nov 2023326023
Dec 2023103010
Jan 20246406
Feb 20245804
Mar 20244000
Apr 20245402
May 20244602
Jun 20246304
Jul 20245403
Aug 20244603
Total854057